• J&J Antibiotic Approved Via 'Animal Rule' Pathway

    • 30 April 2012
    After being backed by a US Food and Drug Administration (FDA) advisory committee , life sciences manufacturer Johnson & Johnson (J&J) has won FDA approval for Levaquin (levofloxacin), an antibiotic intended to treat pneumonic plague. The drug's approval is notable because it utilizes a rarely-used approval pathway known as the 'Animal Rule' pathway. The pathway allows sponsors of products intended to treat very dangerous or contagious conditions to forgo clinica...
  • AstraZeneca CEO Out as New J&J CEO Takes the Helm

    • 26 April 2012
    Two life sciences giants are experiencing transitions in leadership, as AstraZeneca's Chief Executive Office David Brennan announced he was relinquishing his position effective immediately and incoming Johnson & Johnson (J&J) CEO Alex Gorsky assumes his position at the company on 26 April. Rumors of Brennan's departure have been brewing for some time, but finally came to a head after the firm announced a 19% decrease in first-quarter profits, reports Reuters . T...
  • Arkansas Slams J&J With $1.2 Billion Fine for Risperdal Marketing Tactics

    • 12 April 2012
    An Arkansas judge slammed Johnson & Johnson (J&J), the parent company of subsidiary Janssen Pharmaceuticals, with a $1.2 billion dollar fine after Janssen was found to have engaged in deceptive marketing practices for its drug Risperdal, reports The New York Times . Not only is the fine one of the largest monetary penalties ever levied upon a drug company, reports The Times , but it also opens the door for many subsequent lawsuits. "Most attorneys general can ...